| HOME >> BIOLOGY >> TECHNOLOGY |
Confirms commitment to accelerating market penetration and revenue growth
SCOTTSDALE, Ariz., May 1 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today that Scott Robey joined the company as Vice President of Marketing. Most recently Mr. Robey served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C.(R) Therapy brand, during the time US product sales grew from approximately $70 million in 2000 to almost $1.0 billion in 2007.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)
"Scott is a proven leader with a record of successfully developing and executing significant growth strategies. His responsibilities include accelerating market penetration of the Provant Wound Therapy System, and expanding our platform technology into adjacent markets," said Virginia Rybski, Acting President of Regenesis. "Scott complements our senior management team, which has experience in early stage, rapidly developing companies, and management of mid-to-large medical technology organizations."
Mr. Robey is an 18 year marketing veteran. He held marketing positions at KCI, Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.
About the Provant Wound Therapy System
Provant delivers cell proliferation induction(R) (CPI(R)) therapy based
on Regenesis' proprietary pulsed radio frequency energy (PRFE) core
technology platform. PRFE uses an optimized radiofrequency signal to
stimulate dormant cells, causin
'/>"/>
| SOURCE Regenesis Biomedical, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
2. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
5. LifeNet Health(R) Unveils New Biomedical Spine Implant
6. MIT researcher addresses biomedical engineering challenges
7. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
8. Bookham to Enter Biomedical Illumination Market
9. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
10. New NIST mini-sensor may have biomedical and security applications
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |